COMMUNIQUÉS West-GlobeNewswire

Firefly’s AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD
02/06/2026
– Comes just weeks after Firefly confirmed its active public-private partnership with the U.S. Department of War – KENMORE, N.Y, June 02, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company [...]
Aveanna Healthcare Holdings Completes Acquisition of Family First Homecare and Updates Full Year 2026 Guidance
02/06/2026
ATLANTA, June 02, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today [...]
Tris Pharma Announces Presentation on The Complexity and Management of ADHD at Psych Congress Elevate 2026
02/06/2026
Presentation by leading expert Andrew J. Cutler, MD, will examine the lifelong impact of ADHD, risks of leaving the condition untreated, and importance of individualized treatment Presentation will also feature [...]
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
02/06/2026
WAYNE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies [...]
Integra LifeSciences to Present at the 2026 Jefferies Global Healthcare Conference
02/06/2026
PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief financial officer Lea Knight will [...]
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
02/06/2026
Optimi’s 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United States and Europe [...]
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
02/06/2026
Fireside chat scheduled for Tuesday, June 9, 2026, at 2:00 PM ET NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief [...]
Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
02/06/2026
Two regenerative aesthetic and longevity products, with clinically validated ingredients , are expected to reach the U.S. market during 2026, entering a rapidly expanding U.S. medical aesthetics market, projected to [...]
CorVel Marks 35 Years on Nasdaq, Signals Next Phase of Long-Term Innovation and Growth
02/06/2026
FORT WORTH, Texas, June 02, 2026 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) today announced that it will mark its 35th anniversary as a publicly traded company listed on the Nasdaq Stock Market. Members of [...]
Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer
02/06/2026
-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Injectable Ophthalmic Product -- -- Sixth Addition to Late-Stage Pipeline in Seven Months -- CHASKA, Minn., June 02, 2026 ( [...]
Ocugen to Participate in Upcoming June Investor and Industry Conferences
02/06/2026
MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will [...]
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
02/06/2026
Orphan Drug Designation is intended to support the development of therapies for rare diseases affecting fewer than 200,000 people in the United States MIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp [...]
Picard Medical / SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies
02/06/2026
— Independent dual motor ventricular design demonstrates stable full circulatory support across all study procedures — — Advancing second-generation Emperor TAH development toward a fully implantable system — TUCSON, [...]
Augustine Therapeutics to Present Late-Breaking Poster at the American Diabetes Association’s 86th Scientific Sessions
02/06/2026
Poster will feature in vivo efficacy profile of one of Augustine’s HDAC6 inhibitor development candidates LEUVEN, Belgium – 2 June 2026 – Augustine Therapeutics NV (“Augustine” or “the Company”), a biotechnology company [...]
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
02/06/2026
RESEARCH TRIANGLE PARK, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore [...]
Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096
02/06/2026
FDA considered the planned HER-096 Phase 2a study design appropriate Study design finalized; approximately 100 patients to be enrolled More than 50% of Phase 2 funding secured or identified Espoo, Finland, 2 June 2026: [...]
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
02/06/2026
-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 -- BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- [...]
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
02/06/2026
DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial [...]
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
02/06/2026
Meaningful clinical benefit: Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitors Durable survival benefit: 12-month [...]

Pages